Clinical Trial Update: LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations [Phase 2]

View source ↗

Summary

Phase II open-label trial evaluating dabrafenib plus trametinib in unresectable stage III/IV BRAF-mutant melanoma; study completed with posted results focusing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Braf-mutant Melanoma
• Melanoma
• Unresectable Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Stage III Melanoma, Stage IV Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2020-09-07